These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26137087)

  • 1. Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate.
    Sepulveda-Sanchez J; Ramos A; Hilario A; DE Velasco G; Castellano D; Garcia DE LA Torre M; Rodon J; Lahn MF
    Oncol Lett; 2015 Jun; 9(6):2442-2448. PubMed ID: 26137087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.
    Kovacs RJ; Maldonado G; Azaro A; Fernández MS; Romero FL; Sepulveda-Sánchez JM; Corretti M; Carducci M; Dolan M; Gueorguieva I; Cleverly AL; Pillay NS; Baselga J; Lahn MM
    Cardiovasc Toxicol; 2015 Oct; 15(4):309-23. PubMed ID: 25488804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.
    Rodon J; Carducci MA; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly AL; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
    Clin Cancer Res; 2015 Feb; 21(3):553-60. PubMed ID: 25424852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
    Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
    Rodón J; Carducci M; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly A; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
    Invest New Drugs; 2015 Apr; 33(2):357-70. PubMed ID: 25529192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models.
    Mangani D; Weller M; Seyed Sadr E; Willscher E; Seystahl K; Reifenberger G; Tabatabai G; Binder H; Schneider H
    Neuro Oncol; 2016 Dec; 18(12):1610-1621. PubMed ID: 27286797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
    Maier A; Peille AL; Vuaroqueaux V; Lahn M
    Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth-beta 1 contributes to isoflurane postconditioning against cerebral ischemia-reperfusion injury by regulating the c-Jun N-terminal kinase signaling pathway.
    Wang S; Yin J; Ge M; Dai Z; Li Y; Si J; Ma K; Li L; Yao S
    Biomed Pharmacother; 2016 Mar; 78():280-290. PubMed ID: 26898453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer.
    Zhang Q; Hou X; Evans BJ; VanBlaricom JL; Weroha SJ; Cliby WA
    Cancers (Basel); 2018 Aug; 10(8):. PubMed ID: 30087253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.
    Gueorguieva I; Cleverly AL; Stauber A; Sada Pillay N; Rodon JA; Miles CP; Yingling JM; Lahn MM
    Br J Clin Pharmacol; 2014 May; 77(5):796-807. PubMed ID: 24868575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
    Kyritsis AP; Yung WK; Jaeckle KA; Bruner J; Gleason MJ; Ictech SE; Flowers A; Levin VA
    Neurosurgery; 1996 Nov; 39(5):921-6. PubMed ID: 8905746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines.
    Harvey KA; Xu Z; Saaddatzadeh MR; Wang H; Pollok K; Cohen-Gadol AA; Siddiqui RA
    J Neurosurg; 2015 Mar; 122(3):547-56. PubMed ID: 25526274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of transforming growth factor-β inhibitor on the proliferation of glioma stem/progenitor cell.
    Zhang Q; Guo W; Di C; Lou M; Li H; Zhao Y
    Pol J Pathol; 2017; 68(4):312-317. PubMed ID: 29517201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
    Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
    J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.
    Yingling JM; McMillen WT; Yan L; Huang H; Sawyer JS; Graff J; Clawson DK; Britt KS; Anderson BD; Beight DW; Desaiah D; Lahn MM; Benhadji KA; Lallena MJ; Holmgaard RB; Xu X; Zhang F; Manro JR; Iversen PW; Iyer CV; Brekken RA; Kalos MD; Driscoll KE
    Oncotarget; 2018 Jan; 9(6):6659-6677. PubMed ID: 29467918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
    Duerinck J; Du Four S; Sander W; Van Binst AM; Everaert H; Michotte A; Hau P; Neyns B
    Anticancer Res; 2015 Oct; 35(10):5551-7. PubMed ID: 26408725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
    Faivre S; Santoro A; Kelley RK; Gane E; Costentin CE; Gueorguieva I; Smith C; Cleverly A; Lahn MM; Raymond E; Benhadji KA; Giannelli G
    Liver Int; 2019 Aug; 39(8):1468-1477. PubMed ID: 30963691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
    Liu X; Yu M; Chen Y; Zhang J
    Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
    Duerinck J; Du Four S; Bouttens F; Andre C; Verschaeve V; Van Fraeyenhove F; Chaskis C; D'Haene N; Le Mercier M; Rogiers A; Michotte A; Salmon I; Neyns B
    J Neurooncol; 2018 Jan; 136(1):115-125. PubMed ID: 28988341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor beta as a potential tumor progression factor among hyperdiploid glioblastoma cultures: evidence for the role of platelet-derived growth factor.
    Jennings MT; Hart CE; Commers PA; Whitlock JA; Martincic D; Maciunas RJ; Moots PL; Shehab TM
    J Neurooncol; 1997 Feb; 31(3):233-54. PubMed ID: 9049853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.